Patients are significantly more likely to experience treatment-related cardiac events with osimertinib than with other EGFR TKIs, data suggest.

A two-drug combination extended OS compared with standard first-line osimertinib for certain patients with advanced lung ...

The Head and Neck Radiation Oncology Group (GORTEC) announced significant improvement in disease-free survival for locally ...

In this edition of InnovationRx, medical debts will be erased from credit histories, this farm is doubling down on raw milk ...

Johnson & Johnson (J&J) has reported positive topline outcomes from the Phase III MARIPOSA trial of Rybrevant ...

FDA grants priority review tag to JNJ's nipocalimab BLA for gMG and asks for new warnings on GSK & PFE's RSV vaccine labels.

Dame Esther responded after a columnist tried to use her own cancer experience as an argument against assisted dying.

Cullinan Therapeutics’ strong financial position funds growth into 2028. Find out why CGEM stock presents a compelling buy ...

Reaching more mUM patients globally with KIMMTRAK (tebentafusp) in 2025 through additional launches and increased community penetrationEnrolling ...

Johnson & Johnson released results from a phase 3 study, showing that the combination of Rybrevant and Lazcluze significantly improved overall survival in patients with advanced non-small cell lung ...

As a wave of volatility has been re-introduced to the system, investors are flocking toward blue-chip companies for stability ...

Johnson & Johnson announced positive topline results for the gold standard endpoint in cancer treatment of overall survival, or OS, from ...